Chemotherapy for Malignant Pleural Mesothelioma: Past, Present and Future
This paper aims to propose an update on therapeutic medical options for malignant pleural mesothelioma
The key challenge remains to find reliable predictive biomarkers for these innovative, exciting, and expensive treatments to select the best patients for each strategy
Arnaud Scherpereel reports grants from Roche SA and was the principal investigator of clinical trials supported by Roche
This article does not contain any studies with human or animal subjects performed by any of the authors
This article is part of the Topical Collection on Pleural Diseases and Mesothelioma
Need more features? Save interactive summary cards to your Scholarcy Library.